Is Phibro Animal Health (PAHC) overvalued or fairly valued?

MarketChacha shows Phibro Animal Health's valuation in context — a trailing P/E of about 16.2, a forward P/E of about 10.2, a price-to-book of about 4.1 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Phibro Animal Health's reported profit turn into cash?

Over 4 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (1.37×) from reported figures — education, not a rating.

What is Phibro Animal Health's revenue?

Phibro Animal Health reported revenue of $1.5B for FY2026, with net profit of $99.7M, per official filings.

What is the share price of Phibro Animal Health (PAHC)?

Phibro Animal Health last traded at $39.14 (-0.5% on the day), as of 10/20/2026 — a delayed quote shown for education, not investment advice.

Phibro Animal Health

PAHC · NYSE · Healthcare · United States

Snapshot

TickerPAHC

ExchangeNYSE

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

CountryUnited States

Employees2,605

HeadquartersTeaneck, United States

Websitewww.pahc.com

Filings tracked20

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in developing, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, copper, manganese, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for use in personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was incorporated in 1946 and is headquartered in Teaneck, New Jersey.

Who owns it

Insiders0.9%
Institutions99.1%
Public & other0.0%

310 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.15.25%
FMR, LLC14.97%
State Street Corporation4.92%
Millennium Management Llc4.44%
Vanguard Capital Management LLC4.37%
Geode Capital Management, LLC3.11%
Lord, Abbett & Co. LLC3.10%
Dimensional Fund Advisors LP2.52%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Cash conversion1.37×

Over 4 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend3.3% → 6.6%

Margin has expanded by about 3.2 points — the business is getting more profitable.

Return on equity25.9%

Latest ROE of 25.9% — capital is generating a healthy return.

Growth qualityrev 16% · PAT 45%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $393.0M · EPS 0.94

Est. earnings growth +8.0%

Next fiscal year

Rev $1.6B · EPS 3.85

Est. earnings growth +10.1%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2026)

$1.5B

Net margin

6.6%

ROE

25.9%

Revenue CAGR (3y)

+15.8%

Profit CAGR (3y)

+45.2%

EPS (FY2026)

2.43

Net profit (FY2026)

$99.7M

Ask MarketChacha about PAHC

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2026	$1.5B	$99.7M	2.43	6.6%	25.9%
FY2025	$1.3B	$48.3M	1.19	3.7%	16.9%
FY2024	$1.0B	$2.4M	0.06	0.2%	0.9%
FY2023	$977.9M	$32.6M	0.81	3.3%	11.5%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q1	$383.5M	$24.0M	0.59	6.3%
2025Q4	$373.9M	$27.5M	0.67	7.3%
2025Q3	$363.9M	$26.5M	0.65	7.3%
2025Q1	$347.8M	$20.9M	0.51	6.0%
2024Q4	$309.3M	$3.2M	0.08	1.0%
2024Q3	$260.4M	$7.0M	0.17	2.7%
2024Q1	$263.2M	$8.4M	0.21	3.2%
2023Q4	$249.9M	$1.3M	0.03	0.5%
2023Q3	$231.3M	$-8.0M	-0.20	-3.5%
2023Q1	$245.7M	$10.0M	0.25	4.1%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

10-K filing
SEC8/26/2026
8-K — Results of operations, Exhibits
SEC8/26/2026material
8-K — Other events, Exhibits
SEC7/28/2026material
8-K — Executive/director change
SEC6/26/2026material
10-Q filing
SEC5/6/2026
8-K — Results of operations, Exhibits
SEC5/6/2026material
8-K — Other events, Exhibits
SEC5/5/2026material
8-K — Material agreement, Material financial obligation, Exhibits
SEC4/30/2026material
8-K — Reg FD disclosure, Exhibits
SEC4/27/2026material
8-K — Executive/director change
SEC4/14/2026material
10-Q filing
SEC2/4/2026
8-K — Results of operations, Exhibits
SEC2/4/2026material
8-K — Other events, Exhibits
SEC2/3/2026material

2025

8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC12/18/2025material
10-Q filing
SEC11/5/2025
8-K — Results of operations, Shareholder vote results, Exhibits
SEC11/5/2025material
8-K — Other events, Exhibits
SEC11/4/2025material
10-K filing
SEC8/27/2025
8-K — Results of operations, Exhibits
SEC8/27/2025material
8-K — Other events, Exhibits
SEC7/29/2025material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.